ID   MDAH 2774
AC   CVCL_0420
SY   MDAH-2774; MDAH2774; MDA-H2774; 2774; #2774; OV-2774; OV-CA-2774; SK-2774
DR   BTO; BTO:0003942
DR   MCCL; MCC:0000317
DR   AddexBio; C0017001/57
DR   BCRJ; 0163
DR   cancercelllines; CVCL_0420
DR   ChEMBL-Cells; CHEMBL4483147
DR   ChEMBL-Targets; CHEMBL4483256
DR   Cosmic; 724881
DR   Cosmic; 844345
DR   Cosmic; 875291
DR   Cosmic; 897431
DR   Cosmic; 923109
DR   Cosmic; 1044237
DR   Cosmic; 1113282
DR   Cosmic; 1524360
DR   Cosmic; 1708386
DR   Cosmic; 1709262
DR   Cosmic; 2186588
DR   GEO; GSE27654
DR   GEO; GSM1291124
DR   IARC_TP53; 5550
DR   IARC_TP53; 21489
DR   Lonza; 1433
DR   PubChem_Cell_line; CVCL_0420
DR   Wikidata; Q54904669
RX   PubMed=719612;
RX   PubMed=6582512;
RX   PubMed=8557231;
RX   PubMed=9698466;
RX   PubMed=11314036;
RX   PubMed=11565033;
RX   PubMed=12068308;
RX   PubMed=15153938;
RX   PubMed=19288585;
RX   PubMed=22328975;
RX   PubMed=22705003;
RX   PubMed=22710073;
RX   PubMed=25230021;
RX   PubMed=27235858;
CC   Part of: OCCP ovarian cancer cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10303.
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; c.862-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=11565033).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=12068308; PubMed=22705003).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=8557231; PubMed=25230021).
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: BCRJ; 0163; probable.
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
ST   Source(s): AddexBio; ATCC; PubMed=25230021
ST   Amelogenin: X
ST   CSF1PO: 10,11 (PubMed=25230021)
ST   CSF1PO: 10,14 (AddexBio; ATCC)
ST   D13S317: 8,9 (PubMed=25230021)
ST   D13S317: 8,9,12 (AddexBio; ATCC)
ST   D16S539: 10,11,12 (PubMed=25230021)
ST   D16S539: 10,11,12,14 (AddexBio; ATCC)
ST   D18S51: 14,15
ST   D21S11: 30,31
ST   D3S1358: 16,18
ST   D5S818: 10,11,12 (PubMed=25230021)
ST   D5S818: 10,12,13 (AddexBio; ATCC)
ST   D7S820: 8,9.3,10.1,11 (AddexBio; ATCC)
ST   D7S820: 10,11,12 (PubMed=25230021)
ST   D8S1179: 14
ST   FGA: 24,25
ST   Penta D: 13,14
ST   Penta E: 13,14
ST   TH01: 6,8
ST   TPOX: 8 (PubMed=25230021)
ST   TPOX: 8,11 (AddexBio; ATCC)
ST   vWA: 14,16,19,21 (AddexBio; ATCC)
ST   vWA: 15,19 (PubMed=25230021)
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   PubMed=719612; DOI=10.1002/1097-0142(197811)42:5<2352::AID-CNCR2820420536>3.0.CO;2-#;
RA   Freedman R.S., Pihl E., Kusyk C., Gallager H.S., Rutledge F.N.;
RT   "Characterization of an ovarian carcinoma cell line.";
RL   Cancer 42:2352-2359(1978).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=8557231; DOI=10.1006/gyno.1996.0014;
RA   Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.;
RT   "p53 gene mutation analysis and antisense-mediated growth inhibition
RT   of human ovarian carcinoma cell lines.";
RL   Gynecol. Oncol. 60:72-80(1996).
//
RX   PubMed=9698466; DOI=10.1006/gyno.1998.5039;
RA   Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C.,
RA   Berchuck A., Futreal P.A.;
RT   "Mutation of the PTEN tumor suppressor gene is not a feature of
RT   ovarian cancers.";
RL   Gynecol. Oncol. 70:13-16(1998).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=11565033; DOI=10.1038/35095068;
RA   Moberg K.H., Bell D.W., Wahrer D.C.R., Haber D.A., Hariharan I.K.;
RT   "Archipelago regulates cyclin E levels in Drosophila and is mutated in
RT   human cancer cell lines.";
RL   Nature 413:311-316(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=15153938; DOI=10.1038/sj.cgt.7700727;
RA   Quist S.R., Wang-Gohrke S., Kohler T., Kreienberg R., Runnebaum I.B.;
RT   "Cooperative effect of adenoviral p53 gene therapy and standard
RT   chemotherapy in ovarian cancer cells independent of the endogenous p53
RT   status.";
RL   Cancer Gene Ther. 11:547-554(2004).
//
RX   PubMed=19288585; DOI=10.1002/elps.200800505;
RA   Dai L., Li C., Shedden K.A., Misek D.E., Lubman D.M.;
RT   "Comparative proteomic study of two closely related ovarian
RT   endometrioid adenocarcinoma cell lines using cIEF fractionation and
RT   pathway analysis.";
RL   Electrophoresis 30:1119-1131(2009).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22705003; DOI=10.1016/j.humpath.2012.03.011;
RA   Rahman M., Nakayama K., Rahman M.T., Nakayama N., Ishikawa M.,
RA   Katagiri A., Iida K., Nakayama S., Otsuki Y., Shih I.-M.,
RA   Miyazaki K.;
RT   "Clinicopathologic and biological analysis of PIK3CA mutation in
RT   ovarian clear cell carcinoma.";
RL   Hum. Pathol. 43:2197-2206(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=25230021; DOI=10.1371/journal.pone.0103988;
RA   Beaufort C.M., Helmijr J.C.A., Piskorz A.M., Hoogstraat M.,
RA   Ruigrok-Ritstier K., Besselink N., Murtaza M., van IJcken W.F.J.,
RA   Heine A.A.J., Smid M., Koudijs M.J., Brenton J.D., Berns E.M.J.J.,
RA   Helleman J.;
RT   "Ovarian cancer cell line panel (OCCP): clinical importance of in
RT   vitro morphological subtypes.";
RL   PLoS ONE 9:E103988-E103988(2014).
//
RX   PubMed=27235858; DOI=10.1016/j.ygyno.2016.05.028;
RA   Hernandez L., Kim M.K., Lyle L.T., Bunch K.P., House C.D., Ning F.,
RA   Noonan A.M., Annunziata C.M.;
RT   "Characterization of ovarian cancer cell lines as in vivo models for
RT   preclinical studies.";
RL   Gynecol. Oncol. 142:332-340(2016).
//